NCT02605356View on ClinicalTrials.gov

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2016

Primary Completion Date

November 30, 2019

Study Completion Date

July 31, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

DRUG

Placebo

DRUG

Bortezomib

DRUG

Dexamethasone

Trial Locations (58)

1090

Bruxelles - Brussel

1200

Bruxelles - Brussel

3128

Box Hill

4000

Liège

5000

Adelaide

5530

Yvoir

8000

Bruges

10016

Taipei

10126

Turin

11217

Taipei

11528

Athens

12203

Berlin

20014

San Sebastián

20089

Milan

20132

Milan

26500

Rio / Patra

27157

Winston-Salem

27710

Durham

28006

Madrid

28046

Madrid

28100

Novara

31048

Haifa

40138

Bologna

40447

Taichung

41013

Seville

42123

Reggio Emilia

46017

Valencia

50141

Florence

55131

Mainz

56126

Pisa

57201

Watertown

70006

Metairie

72076

Tübingen

72205

Little Rock

81377

München

92024

Encinitas

98104

Seattle

1834111

Afula

5262000

Ramat Gan

6093000

Ẕerifin

9112001

Jerusalem

85259-5404

Scottsdale

20850-6535

Rockville

10032-3729

New York

G1R 2J6

Québec

09121

Cagliari

410-769

Goyang-si

700-701

Daegu

519-763

Jeollanam-do

03080

Seoul

135-710

Seoul

137-701

Seoul

138-736

Seoul

08916

Badalona

08036

Barcelona

07010

Palma de Mallorca

08035

Barcelona

Unknown

Taipei

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY